Viridian Therapeutics Inc VRDN:NASDAQ

Last Price$13.04Cboe Real-Time Last Sale as of 3:22PM ET 5/20/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.03(0.23%)
Bid (Size)$13.01 (21)
Ask (Size)$13.14 (400)
Day Low / High$12.76 - 13.33
Volume126.3 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 05/20/2022


Viridian Therapeutics Inc ( NASDAQ )

Price: $13.04
Change: +0.03 (0.23%)
Volume: 126.3 K
3:22PM ET 5/20/2022

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Liquidia Corp ( NASDAQ )

Price: $5.69
Change: -0.09 (1.56%)
Volume: 457.9 K
3:22PM ET 5/20/2022

Fulcrum Therapeutics Inc ( NASDAQ )

Price: $8.32
Change: -0.32 (3.70%)
Volume: 357.1 K
3:22PM ET 5/20/2022

Arbutus Biopharma Corp ( NASDAQ )

Price: $2.35
Change: +0.01 (0.43%)
Volume: 1.4 M
3:14PM ET 5/20/2022

Read more news Recent News

-- Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q1 Revenue $216,000, vs. Street Est of $254,000
4:10PM ET 5/12/2022 MT Newswires


Insider Sell: Viridian Therapeutics
5:33PM ET 5/04/2022 MT Newswires

Jonathan Violin, Director, Chief Executive Officer, on May 02, 2022, sold 30,000 shares in Viridian Therapeutics (VRDN) for $391,200. Following the Form 4...

Viridian Therapeutics Secures Credit Facility for Up to $75 Million From Hercules Capital
4:36PM ET 4/04/2022 MT Newswires

Viridian Therapeutics (VRDN) said Monday it has struck a debt financing deal with Hercules Capital (HTGC) for up to $75 million. Viridian said it drew an...

Viridian Therapeutics Doses First Subject in Early-Stage Thyroid Eye Disease Trial
5:04PM ET 3/21/2022 MT Newswires

Viridian Therapeutics (VRDN) said Monday it dosed the first subject in an early-stage trial of VRDN-002 for the treatment of thyroid eye disease. The...

Company Profile

Business DescriptionViridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA. View company web site for more details
Address221 Crescent Street
Waltham, Massachusetts 02453
Number of Employees80
Recent SEC Filing05/19/2022SC 13G
President, Chief Executive Officer & DirectorJonathan Violin
Chief Financial, Accounting & Business OfficerKristian Franz Humer
Chief ScientistVahe Bedian
Chief Medical OfficerBarrett Katz

Company Highlights

Price Open$13.16
Previous Close$13.01
52 Week Range$9.47 - 22.00
Market Capitalization$364.2 M
Shares Outstanding27.9 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/10/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$7.69
Beta vs. S&P 500N/A
Revenue$8.4 M
Net Profit Margin-2,680.16%
Return on Equity-53.19%

Analyst Ratings as of 11/17/2021

Consensus RecommendationConsensus Icon
Powered by Factset